CNBC's Jim Cramer reports on the latest news regarding Moderna. This Insane Timelapse From Hubble Will Change Your ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

With the reopening of the Centro de Arte Moderna Gulbenkian, the Portuguese capital is developing a lively contemporary art ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...

“ [Trump’s plans] will come at the expense of potentially larger budget deficits, potentially larger debt and there is also ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Key Takeaways The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated ...

Most U.S. stocks ticked higher to recover some of their sharp slide from last week. The S&P 500 rose 0.4% Monday for its first gain in three days. The Dow Jones Industrial Average slipped 0.1%, and ...